Compare Equinor ASA (EQNR) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinor ASA vs State Street SPDR S&P Biotech ETF — how do they compare? Equinor ASA trades at $43.01 (market cap $101.62B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Equinor ASA is far larger — about 10.1× State Street SPDR S&P Biotech ETF's market cap, and Equinor ASA pays a 3.63% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Equinor ASA for 59 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| EQNR | XBI | |
|---|---|---|
Market Cap | $101.62B | $10.11B |
Volume | 4,991,782 | 12,903,266 |
Sector | Energy | Broad Market / Factor |
52-Week High | $45.75 | $169.55 |
52-Week Low | $22.41 | $104.99 |
Typical Hold Time | 59 Days | 38 Days |
Enterprise Value | $110.31B | — |
Dividend Yield | 3.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EQNR trades at $42.93, up 3.17% today, with a bullish technical outlook supported by moving averages. The stock shows attractive valuation metrics including a P/E of 11.63 and EV/EBITDA of 2.39, while maintaining strong profitability with 21.32% ROE. Recent earnings beat expectations in two of the last three quarters, and the company continues expanding its LNG portfolio with new Asian supply agreements.
EQNR presents compelling value with significant upside to the $87.50 consensus price target. However, declining revenue and net income margins since 2022, coupled with negative net cash flow trends, warrant caution. The stock's performance remains sensitive to energy market volatility and execution of LNG expansion plans through the early 2030s.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
